SlideShare a Scribd company logo
1 of 63
ANALYSIS OF
      DOSE RESPONSE RELATIONSHIP




by Lee Eun Jin
• DOSE = amount of drug administered to the patient

• RESPONSE = effect in the body produced by   the drug

• Drug + Receptor ⇔ Drug-Receptor Complex
                                ⇓
                             Response
Dose-response relationship
   Depends on multiple factors

   A drug usually has one desired effect that causes
    a change in a target organ or structure

   It will also have secondary effects because it will
    be absorbed by other areas of the body
Main effects and side effects

   Main effect – the effect you want the drug to
    have

   Side effects – secondary effects that may or may
    not be desirable or helpful

   Goal is to use a dose of a drug that is effective,
    but has minimal side effects
Dosage-response curve
   Making dosage decision

   Compare dosage to the percentage of people
    showing different effects

   ED10- effective dose where 10% of people show
    response of interest

   Example – dosages of a drug used to increase
    attention (main effect) but also has 2 side effects
    ◦ Heart palpitations
    ◦ death
• The dose-response relationships for drugs may be Graded or quantal.
Graded dose-response curve
• can be constructed for responses that are measured on a continuous scale
• Eg, heart rate.
• Graded dose-response curves relate the intensity of response to the size of
   the dose, and hence are useful for characterizing the actions of drugs.
Quantal dose-response curve
• can be constructed for drugs that elicit an all-or-none response
• Eg, presence or absence of epileptic seizures.
• For most drugs, the doses that are required to produce a specified quantal
   effect in a population are log normally distributed, so that the frequency
   distribution of responses plotted against log dose is a gaussian normal
   distribution curve.
• The percentage of the population requiring a particular dose to exhibit the
   effect can be determined from this curve.
• When these data are plotted as a cumulative frequency distribution, a
   sigmoidal dose-response curve is generated.
Graded dose response
•   means that a slight increase of drug should bring about a small increase in
    the response
•   For example, increase doses of histamine cause gradual contraction of the
    guinea-pig ileum.
•   Very low doses of histamine have virtually no effect and responses can be
    observed, only beyond a threshold does of about 20ng.
•   Again, very high doses of more than 50µg have no additional effects, and
    the response remains constant at this maximal level.
•   Graded dose response means the pharmacological effects of the drugs
    expressed in quality or number, such as the heart rate by beat, blood
    pressure by mmHg, also the contract of ileum in height effected by the
    drugs.
ED50
              GRADE D
              DOSE-
              RE ONSE
                SP
              CURVE
       ED50
• An all-or-none response to a drug and relates to the
frequency with which a            specific dose of a drug
produces a specific response in a population.
• Indicates that a given dose of a drug has or has not
evoked a certain effect in the various subject under
investigation, that is the pharmacological effects are
expressed in passive or negative.
•For example, to test either presence or absence of
hypnosis for a sedative. (e.g., death among the mice in a
pre-clinical study or effective among the patients in a
clinical trial.)
Cumulative
Frequency
Distribution
                     QUANT AL
                     DOSE-
                     RE ONSE
                       SP
                     CURVE

               Frequency
               Distribution
Graded • Continuous scale
                • Measured in a single biologic unit
                • Relates dose to intensity of effect
rate
(%       Dose
) Quantal
           •            All-or-none pharmacologic effect
rat              •      P opulation studies
e
(%)              •      Relates dose to frequency of
                   effect
              Dose
Dose-Response Curve Information

4 Important Values:
 Potency

 Efficacy

 Slope

 Variability
o Absolute amount of drug required to produce an effect

o More potent drug is the one that requires lower do
  to cause same effect



o Measure of amount of drug required for effect
 (ED50)
Potency
• refers to the concentration (EC50) or dose (ED50) of a drug required to produce
   50% of the drug's maximal effect as depicted by a graded dose-response curve.
• EC50 equals KD when there is a linear relationship between occupancy and
   response.
• Often, signal amplification occurs between receptor occupancy and response,
   which results in the EC50 for response being much less (ie, positioned to the left
   on the abscissa of the log dose-response curve) than K D for receptor occupancy.
•   Potency depends on both the affinity of a drug for its receptor, and the
    efficiency with which drug-receptor interaction is coupled to response.
•   The dose of drug required to produce an effect is inversely related to potency.
•   In general, low potency is important only if it results in a need to administer
    the drug in large doses that are impractical.
•   Quantal dose-response curves provide information on the potency of drugs
    that is different from the information derived from graded dose-response
    curves.
•   In a quantal dose-response relationship, the ED 50 is the dose at which 50% of
    individuals exhibit the specified quantal effect
Potency


          A      B
                     Therapeutic
                     Effect
Effect




          Dose
Efficacy (Intrinsic activity)
• THE Ability of the drug to elicit a response when it binds to
   the receptor.
• Conformational changes in receptors as a result of drug
   occupancy initiate biochemical and physiologic events that
   characterize the drug's response.
• In some tissues, agonists demonstrating high efficacy can
   result in a maximal effect, even when only a small fraction of
   the receptors is occupied
Efficacy
   •   Efficacy – how large an effect the drug produces
   •   Maximum effect obtained with drug (not potency)



             100



 Response 50                     2


               0
                    1
                            E 50
                             D
                        L Drug Concentration [M
                         og                    olar]
   Slope: Effect of incremental increase in dose

   change in effect from change in dose
   Variability: Reproducibility of data

   different for different people
   Threshold (minimal) dose
    ◦ Least amount needed to produce desired effects
   Maximum effect
    ◦ Greatest response produced regardless of dose used

                                                 B

                                A
                                                       Therapeutic
                                                       Effect
       Effect




                              Dose
E 50- dose which will be
                                            D
                                           therapeutically effective in
  100                              100
                                           50% of animals (median
                                           effective dose)
T rapeutic
response %

                                           L 50- dose which will, on
                                            D
                                           average, kill 50% of




                                   Death
  50                               50      animals in a population
                                           M D- minimum effective dose
                                             E
 he




                                           (the least dose that is likely
             E 5
              D           L 5
                           D               to be effective).
                                           Also called toxic dose-
             0                             low(T )
                                                 DL
                          0
                 Dosage (mg/
                           kg)             M D- maximum tolerated
                                             T
                                           dose (or minimum toxic
  ME                                       dose) (more than this will
  D                           MT           produce signs of toxicity).
                              D            Also called highest nontoxic
                                           dose (H D)
                                                   NT
Concen tration   Toxic


                 Therapeutic Range

                 Subtherapeutic
Therapeutic index (TI):      The index used for
judging drug's safety.
               TI = LD 50 / ED 50

ED 50



LD 50
Factors Altering Drug Responses

   Age
    ◦ Pediatric or geriatric
    ◦ Immature or decreased hepatic, renal function
   Weight
    ◦ Big patients “spread” drug over larger volume
   Gender
    ◦ Difference in sizes
    ◦ Difference in fat/water distribution
Factors Altering Drug Responses

   Environment
    ◦ Heat or cold
    ◦ Presence or real or perceived threats

 Fever
 Shock
• Toxicity is the degree to which a substance can damage an organism


• Toxicology is the science that deals with the amount
of an agent that causes an adverse action in some living
system

•‘All substances are poisons; there is none which is not
a poison. The right dose differentiates a poison from a
remedy.’- Paracelus (16th century physician-alchemist)

•‘A poison is any substance or matter which, when
applied to the body outwardly, or in any way
introduced into it, can destroy life by its own inherent
qualities, without acting mechanically, and irrespective
Principle causes of drug toxicity/side effects



a. the predictable



b. the less predictable



c. the unpredictable
a.   the predictable
•        excessive action at a primary site (over dosage)
         e.g. anaesthetics, warfarin

         non-selectivity: acting at unrelated sites (more likely with
•       over dosage) e.g. chlorpromazine



•       incomplete selective toxicity: acts against the host as
       well as the target organism or cell
        e.g. protein synthesis inhibitors, antimicrobials, antifungal


•        tolerance (dependence & abuse potential)
         e.g. benzodiazepines, opioids
         unavoidable side-effects
         e.g. immunosuppression by corticosteroids –
         opportunistic infections
a. the predictable


        Pharmacokinetic Drug interactions:


bsorption                        Atropine and
.g. gastric emptying, gut motility
                                 metoclopramide
tribution                       aspirin and warfarin
. displacement from plasma proteins
etabolism                      barbiturates and steroids
g. increased by enzyme induction
xcretion                        NSAIDS and
g. active transport competition methotrexate
a. the predictable


• Age
- most drugs tested on young to middle-aged
volunteers
-causing problems such as:
-drug clearance mechanisms (renal and hepatic) are limited in
 newborns
-clearance is reduced in elderly (increasing half life)
 reduction in lean body mass, serum albumin, total body water.

        increased body fat
        declined renal function
        reduced hepatic blood flow
   •Gender
        reduced activities of cytochrome P450 enzymes
   - a relative increase of body fat in females
b. the less predictable

   • Genetic factors

   e.g. polymorphism in NAT2 in the liver (N-acetyltransferase2).
   -metabolises about 16 common drugs (phenytoin, hydralazine)

   Plasma esterase – suxamethonium (about 1 in 3000
                                individuals)

 c. the unpredictable

           • untoward adverse reactions

           • drug allergies and anaphylactic reactions
            e.g. penicillin (1 in 50,000 patients exposed)
Multiple dosing
   On continuous steady administration of a drug,
    plasma concentration will rise fast at first then
    more slowly and reach a plateau, where:
    rate of administration = rate of elimination i.e.steady
                      state is reached.

Therefore, at steady state:
Dose (Rate of Administration) = clearance x plasma conc.



         steady state conc. = Dose/clearance
Single dose
                                    –
                       7            Loading
                       6            dose
                                                       Therapeutic
 lasma Concentration



                       5                               level

                       4

                       3
                                              Repeated doses
                       2                      –M aintenance
                                              dose
P




                       1

                       0
                           0   5   10    15     20    25     30

                                        Time
• Drug development
  - Site of action
    - Selection of dose and schedule
   - Potency, efficacy and safety
- Drug interactions

 • Patient management

   -Therapeutic drug monitoring
   -Risk benefit (therapeutic indices)
Morphine


           Aspirin
T E
 H RAP UT INDE – AN INDE OF
      E IC    X         X
SAF T
   EY


     Hypnosis   Death
E 99A
                D
           E 50A
            D
L 1A
 D



                          L 1
                           D
       Margin of Safety =
                          ED99
Desired vs undesired effects: Indices
          of drug safety.
• Safety Index
• Therapeutic Index
Safety index: LD1/ED99
                        ED 99
100

80          Sleep                               Death

60

40
                    LD 1
20

 0
                                0



                                            K
       01



       01
        1



               1



                        10




                                                   0K
                    1




-20                                 1K
                             10
            0.
    00




                                         10
    0.
   00




                                                10
 0.
0.
Therapeutic index: LD50/ED50

100

80          Sleep                               Death

60

40

20

 0
                                0



                                            K
       01



       01
        1



               1



                        10




                                                   0K
                    1




-20                                 1K
                             10
            0.
    00




                                         10
    0.
   00




                                                10
 0.
0.
Causes of Variability in Drug Response

    Those related to the biological system
1. Body weight and size
2. Age and Sex
3. Genetics - pharmacogenetics
4. Condition of health
5. Placebo effect
Causes of Variability in Drug Response

• Those related to the conditions of administration
  1. Dose, formulation, route of administration.
  2. Resulting from repeated administration of drug:
       drug resistance; drug tolerance-tachyphylaxis; drug allergy
  3. Drug interactions:
       chemical or physical;
       GI absorption;
       protein binding/distribution;
       metabolism (stimulation/inhibition);
       excretion (pH/transport processes);
       receptor (potentiation/antagonism);
       changes in pH or electrolytes.
Effect site
Dose           Concentration
                                      Effect

 Pharmacokinetics      Pharmacodynamics
 Absorption            Tissue/organ sensitivity
 Distribution               (target status)
 Metabolism
 Elimination
 Drug interactions
Monitoring drug responses
   Level
      Molecular (e.g., enzyme inhibition, receptor

       binding assay)
      Cellular (in vitro tissue culture, blood cells)

      Tissue or organ (in vitro or in vivo)

      Animal disease model


   Endpoint used to measure the effect may be different
    at each level
   Overall effect = Sum of multiple drug effects and
    physiological responses to drug effects
Endpoints to monitor drug effects



      LEVEL       ENDPOINT

      Molecular   Enzyme e inhibition

      Cellular    Proliferation rate, Apoptosis

      Tumor       Response (Change in tumor size)

      Organism    Survival, Quality of life
DOSE-RESPONSE RELATIONSHIPS

 The effect of dose on the
   magnitude of
   pharmacologic
   response.

 Panel A is a linear graph.

              EffectMax • [Drug]
*Effect =
                 KD + [Drug]

* E 50=drug dose that shows fifty
   C
percent of maximal response.
DOSE-RESPONSE RELATIONSHIPS




The effect of dose on
  the magnitude of
  pharmacologic
  response.

Panel B is a
semi-logarithmic plot
  of the same data.
Determinants of Drug Activity
                  1. Potency: the amount of drug to produce an effect
                               of a given magnitude
                  2. Efficacy: the maximal response (effect) produced
                                by drug

                                                                           Morphine
Biologic effect




                                                                                             Codeine
                                 efficacy                    100


                                            Biologic effect(%)
                                                                                                  Aspirin

                                                                 50
                       potency
                                                                   0
                                                                       1      10        100
                    Log dose                                                 Log dose (mg)
DOSE-RESPONSE RELATIONSHIPS



Typical dose-response
  curve
for drugs showing
differences in
potency and efficacy.
DOSE-RESPONSE RELATIONSHIPS




Effects of drug
  antagonists.
DOSE-RESPONSE RELATIONSHIPS


  Effects of partial
    agonists.


                                 Full Agonist


                                 Partial Agonist
ES NOPS E R




                                     Antagonist
              -1    0     1      2
                   Log([A]/KA)
QUANTAL DOSE-RESPONSE RELATIONSHIPS


          Therapeutic Index

 Therapeutic index =
   toxic dose(LD50)/effective dose(EC50)

 This is a measure of a drug’s safety
  • A large number = a wide margin of safety
  • A small number = a small margin of safety
QUANTAL DOSE-RESPONSE RELATIONSHIPS




Effects of partial
  agonists.
QUANTAL DOSE-RESPONSE RELATIONSHIPS


Effects of partial
  agonists.
 Drugs- receptor- response
 Some drugs can act without binding to a receptor
 spare receptors allow maximum response without full receptor
  occupancy
 Efficacy is the amount of drug needed to produce an effect.
 Affinity is the attractiveness between 2 drug molecules.
 Agonist are the drugs that block the response.
 Partial agonist has affinity and maximum efficacy.
 Antagonist has efficacy but no affinity.
 Competitive antagonist decreases potency
 Non competitive antagonist decreases efficacy
THANK YOU

More Related Content

What's hot (20)

Class dose response curve
Class dose response curveClass dose response curve
Class dose response curve
 
Drug response curve
Drug response curveDrug response curve
Drug response curve
 
Bioassay
BioassayBioassay
Bioassay
 
Toxicity
ToxicityToxicity
Toxicity
 
Dose Response Curve
Dose Response CurveDose Response Curve
Dose Response Curve
 
Pharmacodynamics PPT
Pharmacodynamics PPTPharmacodynamics PPT
Pharmacodynamics PPT
 
Therapeutic index
Therapeutic indexTherapeutic index
Therapeutic index
 
DRUG RESPONSE LD50, ED50 AND THERAPEUTIC INDEX-
DRUG RESPONSELD50,ED50 ANDTHERAPEUTIC INDEX-DRUG RESPONSELD50,ED50 ANDTHERAPEUTIC INDEX-
DRUG RESPONSE LD50, ED50 AND THERAPEUTIC INDEX-
 
Principles of toxicology
Principles of toxicologyPrinciples of toxicology
Principles of toxicology
 
Factors affecting biotransformation of drugs
Factors affecting biotransformation of drugsFactors affecting biotransformation of drugs
Factors affecting biotransformation of drugs
 
Bioassay
BioassayBioassay
Bioassay
 
Zero order and first order kinetiks
Zero order and first order kinetiksZero order and first order kinetiks
Zero order and first order kinetiks
 
Adme
AdmeAdme
Adme
 
Drug distribution
Drug distributionDrug distribution
Drug distribution
 
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
 
Pharmacodynamics.pptx
Pharmacodynamics.pptxPharmacodynamics.pptx
Pharmacodynamics.pptx
 
Pharmacodynamics
Pharmacodynamics Pharmacodynamics
Pharmacodynamics
 
CARCINOGENICITY
CARCINOGENICITYCARCINOGENICITY
CARCINOGENICITY
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animals
 
Combined effects of Drugs, Pharmacology
Combined effects of Drugs, PharmacologyCombined effects of Drugs, Pharmacology
Combined effects of Drugs, Pharmacology
 

Similar to 2. dose resp relationsp presentsn copy - copy

Drug Dose Response Relationship Pharmacology.pptx
Drug Dose Response Relationship Pharmacology.pptxDrug Dose Response Relationship Pharmacology.pptx
Drug Dose Response Relationship Pharmacology.pptxSunilSingh790653
 
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]BADAR UDDIN UMAR
 
Consequences of drug receptor interactions
Consequences of drug receptor interactionsConsequences of drug receptor interactions
Consequences of drug receptor interactionsJannatul Ferdoush
 
Pharmacodynamics revised
Pharmacodynamics   revisedPharmacodynamics   revised
Pharmacodynamics revisedOmar Moatamed
 
Drug Response.pptx
Drug Response.pptxDrug Response.pptx
Drug Response.pptxFarazaJaved
 
Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)MuhammadImranulhaq3
 
branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...adnan mansour
 
Pharmacodynamics.2020
Pharmacodynamics.2020Pharmacodynamics.2020
Pharmacodynamics.2020adnan mansour
 
Pharmacodynamics 2020
Pharmacodynamics 2020 Pharmacodynamics 2020
Pharmacodynamics 2020 adnan mansour
 
Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)Priyansha Singh
 
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...Imhotep Virtual Medical School
 
Principles of pharmacodynamics
Principles of pharmacodynamicsPrinciples of pharmacodynamics
Principles of pharmacodynamicsJaineel Dharod
 
Pharmacodynamics.pptx
Pharmacodynamics.pptxPharmacodynamics.pptx
Pharmacodynamics.pptxayman255825
 
Dose-Response of drugs towards the human body
Dose-Response of drugs towards the human bodyDose-Response of drugs towards the human body
Dose-Response of drugs towards the human bodyTabassum Saher
 
Comparison of reversible and irreversible antagonists (Dose-response.pptx
Comparison of reversible and irreversible antagonists (Dose-response.pptxComparison of reversible and irreversible antagonists (Dose-response.pptx
Comparison of reversible and irreversible antagonists (Dose-response.pptxAbdalrahmanyousefSal
 

Similar to 2. dose resp relationsp presentsn copy - copy (20)

Drug Dose Response Relationship Pharmacology.pptx
Drug Dose Response Relationship Pharmacology.pptxDrug Dose Response Relationship Pharmacology.pptx
Drug Dose Response Relationship Pharmacology.pptx
 
Dose response curvevpp
Dose response curvevppDose response curvevpp
Dose response curvevpp
 
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
 
Consequences of drug receptor interactions
Consequences of drug receptor interactionsConsequences of drug receptor interactions
Consequences of drug receptor interactions
 
Pharmacodynamics revised
Pharmacodynamics   revisedPharmacodynamics   revised
Pharmacodynamics revised
 
Drug Response.pptx
Drug Response.pptxDrug Response.pptx
Drug Response.pptx
 
Pharmacology pdf
Pharmacology pdfPharmacology pdf
Pharmacology pdf
 
Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)
 
branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...
 
Pharmacodynamics.2020
Pharmacodynamics.2020Pharmacodynamics.2020
Pharmacodynamics.2020
 
Pharmacodynamics 2020
Pharmacodynamics 2020 Pharmacodynamics 2020
Pharmacodynamics 2020
 
PHARMACOKINETICS BScN.pptx
PHARMACOKINETICS BScN.pptxPHARMACOKINETICS BScN.pptx
PHARMACOKINETICS BScN.pptx
 
Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)
 
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...
IVMS-GENERAL PRINCIPLES OF PHARMACOLOGY- Pharmacodynamics-Dose-Response Curve...
 
Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Principles of pharmacodynamics
Principles of pharmacodynamicsPrinciples of pharmacodynamics
Principles of pharmacodynamics
 
Affinity and Efficacy
Affinity and EfficacyAffinity and Efficacy
Affinity and Efficacy
 
Pharmacodynamics.pptx
Pharmacodynamics.pptxPharmacodynamics.pptx
Pharmacodynamics.pptx
 
Dose-Response of drugs towards the human body
Dose-Response of drugs towards the human bodyDose-Response of drugs towards the human body
Dose-Response of drugs towards the human body
 
Comparison of reversible and irreversible antagonists (Dose-response.pptx
Comparison of reversible and irreversible antagonists (Dose-response.pptxComparison of reversible and irreversible antagonists (Dose-response.pptx
Comparison of reversible and irreversible antagonists (Dose-response.pptx
 

More from suniu

RA.ppt
RA.pptRA.ppt
RA.pptsuniu
 
anti-protozoan.pptx
anti-protozoan.pptxanti-protozoan.pptx
anti-protozoan.pptxsuniu
 
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDF
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDFHISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDF
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDFsuniu
 
Nsaids veterinary pharmacology
Nsaids   veterinary pharmacologyNsaids   veterinary pharmacology
Nsaids veterinary pharmacologysuniu
 
3. molecular mech of drug action presentn
3. molecular mech  of drug action presentn3. molecular mech  of drug action presentn
3. molecular mech of drug action presentnsuniu
 
1. theories of d r intersctn presentn
1. theories of d r intersctn presentn1. theories of d r intersctn presentn
1. theories of d r intersctn presentnsuniu
 
Xenosensors
XenosensorsXenosensors
Xenosensorssuniu
 
Principles and application of chromatography
Principles and application of chromatographyPrinciples and application of chromatography
Principles and application of chromatographysuniu
 
Immunodiffusion principles and application
Immunodiffusion principles and  applicationImmunodiffusion principles and  application
Immunodiffusion principles and applicationsuniu
 
Ultrsonography Principle and application
Ultrsonography Principle and applicationUltrsonography Principle and application
Ultrsonography Principle and applicationsuniu
 
Spectrophotometry
SpectrophotometrySpectrophotometry
Spectrophotometrysuniu
 
Electron microscopy
Electron microscopyElectron microscopy
Electron microscopysuniu
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolismsuniu
 
Drug excretion
Drug  excretionDrug  excretion
Drug excretionsuniu
 
Drug distribution
Drug  distributionDrug  distribution
Drug distributionsuniu
 
Veterinary gasteroenterolgy
Veterinary gasteroenterolgyVeterinary gasteroenterolgy
Veterinary gasteroenterolgysuniu
 
Poisonous plants of vety importance
Poisonous plants  of vety importancePoisonous plants  of vety importance
Poisonous plants of vety importancesuniu
 
Veterinary antineoplastic drugs
Veterinary antineoplastic drugsVeterinary antineoplastic drugs
Veterinary antineoplastic drugssuniu
 
Household substance toxic to pets
Household substance toxic to petsHousehold substance toxic to pets
Household substance toxic to petssuniu
 
Cephalosporins penems
Cephalosporins  penemsCephalosporins  penems
Cephalosporins penemssuniu
 

More from suniu (20)

RA.ppt
RA.pptRA.ppt
RA.ppt
 
anti-protozoan.pptx
anti-protozoan.pptxanti-protozoan.pptx
anti-protozoan.pptx
 
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDF
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDFHISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDF
HISTORY pharmacology DRUG NOMENCLATURE CLINICAL TRIALS.PDF
 
Nsaids veterinary pharmacology
Nsaids   veterinary pharmacologyNsaids   veterinary pharmacology
Nsaids veterinary pharmacology
 
3. molecular mech of drug action presentn
3. molecular mech  of drug action presentn3. molecular mech  of drug action presentn
3. molecular mech of drug action presentn
 
1. theories of d r intersctn presentn
1. theories of d r intersctn presentn1. theories of d r intersctn presentn
1. theories of d r intersctn presentn
 
Xenosensors
XenosensorsXenosensors
Xenosensors
 
Principles and application of chromatography
Principles and application of chromatographyPrinciples and application of chromatography
Principles and application of chromatography
 
Immunodiffusion principles and application
Immunodiffusion principles and  applicationImmunodiffusion principles and  application
Immunodiffusion principles and application
 
Ultrsonography Principle and application
Ultrsonography Principle and applicationUltrsonography Principle and application
Ultrsonography Principle and application
 
Spectrophotometry
SpectrophotometrySpectrophotometry
Spectrophotometry
 
Electron microscopy
Electron microscopyElectron microscopy
Electron microscopy
 
Drug metabolism
Drug metabolismDrug metabolism
Drug metabolism
 
Drug excretion
Drug  excretionDrug  excretion
Drug excretion
 
Drug distribution
Drug  distributionDrug  distribution
Drug distribution
 
Veterinary gasteroenterolgy
Veterinary gasteroenterolgyVeterinary gasteroenterolgy
Veterinary gasteroenterolgy
 
Poisonous plants of vety importance
Poisonous plants  of vety importancePoisonous plants  of vety importance
Poisonous plants of vety importance
 
Veterinary antineoplastic drugs
Veterinary antineoplastic drugsVeterinary antineoplastic drugs
Veterinary antineoplastic drugs
 
Household substance toxic to pets
Household substance toxic to petsHousehold substance toxic to pets
Household substance toxic to pets
 
Cephalosporins penems
Cephalosporins  penemsCephalosporins  penems
Cephalosporins penems
 

Recently uploaded

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701bronxfugly43
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxcallscotland1987
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structuredhanjurrannsibayan2
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseAnaAcapella
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.MaryamAhmad92
 

Recently uploaded (20)

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 

2. dose resp relationsp presentsn copy - copy

  • 1. ANALYSIS OF DOSE RESPONSE RELATIONSHIP by Lee Eun Jin
  • 2. • DOSE = amount of drug administered to the patient • RESPONSE = effect in the body produced by the drug • Drug + Receptor ⇔ Drug-Receptor Complex ⇓ Response
  • 3. Dose-response relationship  Depends on multiple factors  A drug usually has one desired effect that causes a change in a target organ or structure  It will also have secondary effects because it will be absorbed by other areas of the body
  • 4. Main effects and side effects  Main effect – the effect you want the drug to have  Side effects – secondary effects that may or may not be desirable or helpful  Goal is to use a dose of a drug that is effective, but has minimal side effects
  • 5. Dosage-response curve  Making dosage decision  Compare dosage to the percentage of people showing different effects  ED10- effective dose where 10% of people show response of interest  Example – dosages of a drug used to increase attention (main effect) but also has 2 side effects ◦ Heart palpitations ◦ death
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. • The dose-response relationships for drugs may be Graded or quantal. Graded dose-response curve • can be constructed for responses that are measured on a continuous scale • Eg, heart rate. • Graded dose-response curves relate the intensity of response to the size of the dose, and hence are useful for characterizing the actions of drugs. Quantal dose-response curve • can be constructed for drugs that elicit an all-or-none response • Eg, presence or absence of epileptic seizures. • For most drugs, the doses that are required to produce a specified quantal effect in a population are log normally distributed, so that the frequency distribution of responses plotted against log dose is a gaussian normal distribution curve. • The percentage of the population requiring a particular dose to exhibit the effect can be determined from this curve. • When these data are plotted as a cumulative frequency distribution, a sigmoidal dose-response curve is generated.
  • 11. Graded dose response • means that a slight increase of drug should bring about a small increase in the response • For example, increase doses of histamine cause gradual contraction of the guinea-pig ileum. • Very low doses of histamine have virtually no effect and responses can be observed, only beyond a threshold does of about 20ng. • Again, very high doses of more than 50µg have no additional effects, and the response remains constant at this maximal level. • Graded dose response means the pharmacological effects of the drugs expressed in quality or number, such as the heart rate by beat, blood pressure by mmHg, also the contract of ileum in height effected by the drugs.
  • 12. ED50 GRADE D DOSE- RE ONSE SP CURVE ED50
  • 13. • An all-or-none response to a drug and relates to the frequency with which a specific dose of a drug produces a specific response in a population. • Indicates that a given dose of a drug has or has not evoked a certain effect in the various subject under investigation, that is the pharmacological effects are expressed in passive or negative. •For example, to test either presence or absence of hypnosis for a sedative. (e.g., death among the mice in a pre-clinical study or effective among the patients in a clinical trial.)
  • 14. Cumulative Frequency Distribution QUANT AL DOSE- RE ONSE SP CURVE Frequency Distribution
  • 15. Graded • Continuous scale • Measured in a single biologic unit • Relates dose to intensity of effect rate (% Dose ) Quantal • All-or-none pharmacologic effect rat • P opulation studies e (%) • Relates dose to frequency of effect Dose
  • 16. Dose-Response Curve Information 4 Important Values:  Potency  Efficacy  Slope  Variability
  • 17. o Absolute amount of drug required to produce an effect o More potent drug is the one that requires lower do to cause same effect o Measure of amount of drug required for effect (ED50)
  • 18. Potency • refers to the concentration (EC50) or dose (ED50) of a drug required to produce 50% of the drug's maximal effect as depicted by a graded dose-response curve. • EC50 equals KD when there is a linear relationship between occupancy and response. • Often, signal amplification occurs between receptor occupancy and response, which results in the EC50 for response being much less (ie, positioned to the left on the abscissa of the log dose-response curve) than K D for receptor occupancy. • Potency depends on both the affinity of a drug for its receptor, and the efficiency with which drug-receptor interaction is coupled to response. • The dose of drug required to produce an effect is inversely related to potency. • In general, low potency is important only if it results in a need to administer the drug in large doses that are impractical. • Quantal dose-response curves provide information on the potency of drugs that is different from the information derived from graded dose-response curves. • In a quantal dose-response relationship, the ED 50 is the dose at which 50% of individuals exhibit the specified quantal effect
  • 19. Potency A B Therapeutic Effect Effect Dose
  • 20. Efficacy (Intrinsic activity) • THE Ability of the drug to elicit a response when it binds to the receptor. • Conformational changes in receptors as a result of drug occupancy initiate biochemical and physiologic events that characterize the drug's response. • In some tissues, agonists demonstrating high efficacy can result in a maximal effect, even when only a small fraction of the receptors is occupied
  • 21. Efficacy • Efficacy – how large an effect the drug produces • Maximum effect obtained with drug (not potency) 100 Response 50 2 0 1 E 50 D L Drug Concentration [M og olar]
  • 22. Slope: Effect of incremental increase in dose  change in effect from change in dose
  • 23. Variability: Reproducibility of data  different for different people
  • 24. Threshold (minimal) dose ◦ Least amount needed to produce desired effects  Maximum effect ◦ Greatest response produced regardless of dose used B A Therapeutic Effect Effect Dose
  • 25. E 50- dose which will be D therapeutically effective in 100 100 50% of animals (median effective dose) T rapeutic response % L 50- dose which will, on D average, kill 50% of Death 50 50 animals in a population M D- minimum effective dose E he (the least dose that is likely E 5 D L 5 D to be effective). Also called toxic dose- 0 low(T ) DL 0 Dosage (mg/ kg) M D- maximum tolerated T dose (or minimum toxic ME dose) (more than this will D MT produce signs of toxicity). D Also called highest nontoxic dose (H D) NT
  • 26. Concen tration Toxic Therapeutic Range Subtherapeutic
  • 27. Therapeutic index (TI): The index used for judging drug's safety. TI = LD 50 / ED 50 ED 50 LD 50
  • 28. Factors Altering Drug Responses  Age ◦ Pediatric or geriatric ◦ Immature or decreased hepatic, renal function  Weight ◦ Big patients “spread” drug over larger volume  Gender ◦ Difference in sizes ◦ Difference in fat/water distribution
  • 29. Factors Altering Drug Responses  Environment ◦ Heat or cold ◦ Presence or real or perceived threats  Fever  Shock
  • 30. • Toxicity is the degree to which a substance can damage an organism • Toxicology is the science that deals with the amount of an agent that causes an adverse action in some living system •‘All substances are poisons; there is none which is not a poison. The right dose differentiates a poison from a remedy.’- Paracelus (16th century physician-alchemist) •‘A poison is any substance or matter which, when applied to the body outwardly, or in any way introduced into it, can destroy life by its own inherent qualities, without acting mechanically, and irrespective
  • 31. Principle causes of drug toxicity/side effects a. the predictable b. the less predictable c. the unpredictable
  • 32. a. the predictable • excessive action at a primary site (over dosage) e.g. anaesthetics, warfarin non-selectivity: acting at unrelated sites (more likely with • over dosage) e.g. chlorpromazine • incomplete selective toxicity: acts against the host as well as the target organism or cell e.g. protein synthesis inhibitors, antimicrobials, antifungal • tolerance (dependence & abuse potential) e.g. benzodiazepines, opioids unavoidable side-effects e.g. immunosuppression by corticosteroids – opportunistic infections
  • 33. a. the predictable Pharmacokinetic Drug interactions: bsorption Atropine and .g. gastric emptying, gut motility metoclopramide tribution aspirin and warfarin . displacement from plasma proteins etabolism barbiturates and steroids g. increased by enzyme induction xcretion NSAIDS and g. active transport competition methotrexate
  • 34. a. the predictable • Age - most drugs tested on young to middle-aged volunteers -causing problems such as: -drug clearance mechanisms (renal and hepatic) are limited in newborns -clearance is reduced in elderly (increasing half life) reduction in lean body mass, serum albumin, total body water. increased body fat declined renal function reduced hepatic blood flow •Gender reduced activities of cytochrome P450 enzymes - a relative increase of body fat in females
  • 35. b. the less predictable • Genetic factors e.g. polymorphism in NAT2 in the liver (N-acetyltransferase2). -metabolises about 16 common drugs (phenytoin, hydralazine) Plasma esterase – suxamethonium (about 1 in 3000 individuals) c. the unpredictable • untoward adverse reactions • drug allergies and anaphylactic reactions e.g. penicillin (1 in 50,000 patients exposed)
  • 36. Multiple dosing  On continuous steady administration of a drug, plasma concentration will rise fast at first then more slowly and reach a plateau, where: rate of administration = rate of elimination i.e.steady state is reached. Therefore, at steady state: Dose (Rate of Administration) = clearance x plasma conc. steady state conc. = Dose/clearance
  • 37. Single dose – 7 Loading 6 dose Therapeutic lasma Concentration 5 level 4 3 Repeated doses 2 –M aintenance dose P 1 0 0 5 10 15 20 25 30 Time
  • 38. • Drug development - Site of action - Selection of dose and schedule - Potency, efficacy and safety - Drug interactions • Patient management -Therapeutic drug monitoring -Risk benefit (therapeutic indices)
  • 39.
  • 40. Morphine Aspirin
  • 41. T E H RAP UT INDE – AN INDE OF E IC X X SAF T EY Hypnosis Death
  • 42. E 99A D E 50A D L 1A D L 1 D Margin of Safety = ED99
  • 43. Desired vs undesired effects: Indices of drug safety. • Safety Index • Therapeutic Index
  • 44. Safety index: LD1/ED99 ED 99 100 80 Sleep Death 60 40 LD 1 20 0 0 K 01 01 1 1 10 0K 1 -20 1K 10 0. 00 10 0. 00 10 0. 0.
  • 45. Therapeutic index: LD50/ED50 100 80 Sleep Death 60 40 20 0 0 K 01 01 1 1 10 0K 1 -20 1K 10 0. 00 10 0. 00 10 0. 0.
  • 46. Causes of Variability in Drug Response Those related to the biological system 1. Body weight and size 2. Age and Sex 3. Genetics - pharmacogenetics 4. Condition of health 5. Placebo effect
  • 47. Causes of Variability in Drug Response • Those related to the conditions of administration 1. Dose, formulation, route of administration. 2. Resulting from repeated administration of drug: drug resistance; drug tolerance-tachyphylaxis; drug allergy 3. Drug interactions: chemical or physical; GI absorption; protein binding/distribution; metabolism (stimulation/inhibition); excretion (pH/transport processes); receptor (potentiation/antagonism); changes in pH or electrolytes.
  • 48. Effect site Dose Concentration Effect Pharmacokinetics Pharmacodynamics Absorption Tissue/organ sensitivity Distribution (target status) Metabolism Elimination Drug interactions
  • 49. Monitoring drug responses  Level  Molecular (e.g., enzyme inhibition, receptor binding assay)  Cellular (in vitro tissue culture, blood cells)  Tissue or organ (in vitro or in vivo)  Animal disease model  Endpoint used to measure the effect may be different at each level  Overall effect = Sum of multiple drug effects and physiological responses to drug effects
  • 50. Endpoints to monitor drug effects LEVEL ENDPOINT Molecular Enzyme e inhibition Cellular Proliferation rate, Apoptosis Tumor Response (Change in tumor size) Organism Survival, Quality of life
  • 51. DOSE-RESPONSE RELATIONSHIPS The effect of dose on the magnitude of pharmacologic response. Panel A is a linear graph. EffectMax • [Drug] *Effect = KD + [Drug] * E 50=drug dose that shows fifty C percent of maximal response.
  • 52. DOSE-RESPONSE RELATIONSHIPS The effect of dose on the magnitude of pharmacologic response. Panel B is a semi-logarithmic plot of the same data.
  • 53. Determinants of Drug Activity 1. Potency: the amount of drug to produce an effect of a given magnitude 2. Efficacy: the maximal response (effect) produced by drug Morphine Biologic effect Codeine efficacy 100 Biologic effect(%) Aspirin 50 potency 0 1 10 100 Log dose Log dose (mg)
  • 54. DOSE-RESPONSE RELATIONSHIPS Typical dose-response curve for drugs showing differences in potency and efficacy.
  • 56. DOSE-RESPONSE RELATIONSHIPS Effects of partial agonists. Full Agonist Partial Agonist ES NOPS E R Antagonist -1 0 1 2 Log([A]/KA)
  • 57. QUANTAL DOSE-RESPONSE RELATIONSHIPS Therapeutic Index  Therapeutic index = toxic dose(LD50)/effective dose(EC50)  This is a measure of a drug’s safety • A large number = a wide margin of safety • A small number = a small margin of safety
  • 60.
  • 61.
  • 62.  Drugs- receptor- response  Some drugs can act without binding to a receptor  spare receptors allow maximum response without full receptor occupancy  Efficacy is the amount of drug needed to produce an effect.  Affinity is the attractiveness between 2 drug molecules.  Agonist are the drugs that block the response.  Partial agonist has affinity and maximum efficacy.  Antagonist has efficacy but no affinity.  Competitive antagonist decreases potency  Non competitive antagonist decreases efficacy